Biotech, Food, Drug

The food we eat and the medicine we put into our bodies are highly regulated by a variety of government agencies. In the United States by the Food and Drug Administration (FDA) and the United States Department of Agriculture (USDA) regulate the processes by which food makes its way to the grocery store and medicine is approved for consumer use.  As the science grows more complex behind the pharmaceutical and food industry, interpretation of the regulations in place is becoming more nuanced.  Overseas, these industries are regulated by a variety of agencies; for example, the Minister of Agriculture in Canada, Centre for Food Safety in Hong Kong, and the Committee of Environmental, Public Health and Food Safety (EU), are among the many governing-bodies which regulate biotechnology, food, and drugs throughout the world.

The National Law Review is your free online resource to agency news, emerging topics in food and drug, and the latest in biotechnology updates. From nanotechnologies being used in research, to regulations of imported foods coming into the US from overseas or the development of medical devices and drugs, readers can find expert legal analysis of the developments in the industry, as well as reports on changes within the agencies that regulate these industries. The National Law Review also covers topics related to licensing, Food Safety and Inspection Services (FSIS), food and beverage regulation in the US and worldwide, nutrition labeling, and country of origin labeling guidelines.

With recent legislation being passed throughout the US in relation to marijuana use, both for recreational and medicinal purposes, readers will also find up-to-date information, litigation, and news coming from this area of interest as well. Regulations in California for labeling and proper sales of marijuana, to use in different states, or internationally, as well as rules for promoting and advertising marijuana are also covered on the site. Additionally, the development and changing landscape of tobacco use to include vaping, and how e-cigarettes and vaping are regulated, is also covered by NLR authors.

Readers who are interested in food safety, inspection, imports into the US, and regulations, these topics are covered regularly on The National Law Review as well. New legislation from the FDA, USDA, Department of Agriculture, and international bodies, are covered on the site. If you are looking for details on new nutrition-labeling regulations or health risks of consuming certain imported foods, you will find these topics, and many more, on The National Law Review.

For hourly updates on the latest news about biotech, food & drug, and cannabis laws, regulations, and legislation, be sure to follow our Cannabis Twitter feed, and sign up for complimentary e-news bulletins.

Custom text Title Organization Sort descending
Jul
27
2023
FDA Maintains Focus on “Intended Use” for Software-Enabled Medical Devices Sheppard, Mullin, Richter & Hampton LLP
Mar
30
2020
Key Health Care Provisions of the Coronavirus Aid, Relief, and Economic Security Act (the “CARES Act”) Sheppard, Mullin, Richter & Hampton LLP
Apr
9
2020
Update: Key FDA Actions for COVID-19 Devices and Therapies Sheppard, Mullin, Richter & Hampton LLP
Apr
24
2020
As America Prepares to Return to Work, EEOC Approves Testing Employees for COVID-19 Sheppard, Mullin, Richter & Hampton LLP
Nov
10
2023
From Good Reprint Practices to SIUU Communications: What Firms Need to Know Sheppard, Mullin, Richter & Hampton LLP
Jul
9
2020
COVID-19’s Continued Impacts on Cannabis Operators Sheppard, Mullin, Richter & Hampton LLP
Aug
17
2020
County Zoning Ordinance Cannot be Used to Justify Property Seizure Sheppard, Mullin, Richter & Hampton LLP
Sep
16
2020
Latest Update on FDA’s Software Pre-Cert Pilot Program Sheppard, Mullin, Richter & Hampton LLP
Apr
26
2013
Delaware Supreme Court Affirms Preclusive Effect of Non-Delaware Dismissals and Rejects Irrebuttable Presumption That a Derivative Plaintiff Who Fails to Conduct a Section 220 Inspection Is an Inadequate Representative Sheppard, Mullin, Richter & Hampton LLP
May
2
2013
Can California Cap and Trade if Brussels Stumbles? Sheppard, Mullin, Richter & Hampton LLP
Apr
13
2018
Health Plans and Pharmacy Benefit Managers – Past and Future Sheppard, Mullin, Richter & Hampton LLP
Sep
27
2013
Details: Highlights from the August & September 2013 Federal Register Sheppard, Mullin, Richter & Hampton LLP
Dec
13
2021
Debate Continues Around Scope of Practice Expansion for APPs Sheppard, Mullin, Richter & Hampton LLP
Nov
29
2018
CMS Issues Proposed Rule on Modernizing Part D and Medicare Advantage to Lower Drug Prices and Reduce Out-of-Pocket Expenses Sheppard, Mullin, Richter & Hampton LLP
Apr
26
2014
Preexisting Management Plan Not a “Mitigation Measure” for Purposes of California Environmental Quality Act (CEQA) Exemption Sheppard, Mullin, Richter & Hampton LLP
Apr
18
2022
Sow What Now?: Cal. Hispanic Chambers of Commerce et. al. v. Ross et. al., The U.S. Supreme Court, and California’s Proposition 12 Sheppard, Mullin, Richter & Hampton LLP
Mar
30
2019
Second Circuit Affirms “Snap” Removal Practice Sheppard, Mullin, Richter & Hampton LLP
Jun
20
2022
Supreme Court Saves Hospitals from $1.6B Cut to 340B Program Sheppard, Mullin, Richter & Hampton LLP
Jun
23
2022
FDA Issues Untitled Letter to Althera Pharmaceuticals for Statements Relating to ROSZET® Sheppard, Mullin, Richter & Hampton LLP
Dec
27
2022
FDA Expands Inspection Guidance to Apply to Device Manufacturers Sheppard, Mullin, Richter & Hampton LLP
Mar
7
2023
DEA Proposes Rule for Post-PHE Telemedicine Sheppard, Mullin, Richter & Hampton LLP
Apr
26
2023
Withdrawal of Drug Approval Highlights Risk of Accelerated Approval Pathway Sheppard, Mullin, Richter & Hampton LLP
Jun
14
2023
New York Landlords May Get Stuck with the Bill for Unlicensed Cannabis Sticker Shops Sheppard, Mullin, Richter & Hampton LLP
Jun
21
2023
The Drug Price Negotiation Program Faces Pushback from Private and Public Industry Participants Sheppard, Mullin, Richter & Hampton LLP
Jul
19
2016
Forget About Vermont!: Congress Passes GMO “Labeling” Legislation Sheppard, Mullin, Richter & Hampton LLP
Feb
5
2024
Cannabis Rescheduling: HHS Findings and Legal Implications Sheppard, Mullin, Richter & Hampton LLP
Apr
1
2024
FDCA Preemption: A Powerful Tool for Defending Class Actions Sheppard, Mullin, Richter & Hampton LLP
Nov
18
2020
Green Wave: The Latest Election Cycle Brings Hope for Standardized Cannabis Legalization Sheppard, Mullin, Richter & Hampton LLP
Nov
23
2020
Los Angeles County Restricts In-Person Dining Due to Surge in COVID-19 Cases Sheppard, Mullin, Richter & Hampton LLP
Dec
12
2011
FDA Announces Proposals for Biosimilars User Fees and Performance Review Goals Sheppard, Mullin, Richter & Hampton LLP
Apr
17
2013
Utility Pole Not A Point Source Under The Clean Water Act Sheppard, Mullin, Richter & Hampton LLP
Aug
9
2021
California Breaks New Ground With OCal: Answers to Key Questions About “Comparable-to-Organic” Cannabis Sheppard, Mullin, Richter & Hampton LLP
Jul
6
2013
A Short-Lived Victory for Generic Drug Manufacturers? Sheppard, Mullin, Richter & Hampton LLP
Nov
6
2013
Supreme Court Grants Limited Review of Greenhouse Gas Emissions Regulations Sheppard, Mullin, Richter & Hampton LLP
Feb
16
2022
Restructure This! Episode 3: Canada: Cannabis Boom or Bust? [PODCAST] Sheppard, Mullin, Richter & Hampton LLP
 

NLR Logo

We collaborate with the world's leading lawyers to deliver news tailored for you. Sign Up to receive our free e-Newsbulletins

 

Sign Up for e-NewsBulletins